Quantcast

Latest Bayer HealthCare AG Stories

2014-08-05 08:30:34

LONDON, Aug. 5, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Glucose Monitoring Device Market to 2019 - Technology Adoption and Increasing Health Awareness Serve as Distinct Regional Growth Drivershttp://www.reportbuyer.com/pharma_healthcare/medical_supplies/hospital_supplies/glucose_monitoring_device_market_2019_technology_adoption_increasing_health_awareness_serve_distinct_regional_growth_drivers.htmlGlucose Monitoring Device Market to 2019 -...

2014-07-28 20:24:28

LONDON, July 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Medical Biosensors Market 2014-2018https://www.reportbuyer.com/product/403457/Global-Medical-Biosensors-Market-2014-2018.htmlAboutMedical biosensors are used to analyze biological components with the help of physicochemical detectors. These biosensors monitor health status, disease betterment, and therapeutic treatment outcomes through invasive and non-invasive methods. They are...

2014-05-27 12:31:59

LONDON, May 27, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Global Pain Management Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_pain_management_drugs_market_2014_2018.html TechNavio's analysts forecast the Global Pain Management Drugs market will grow at a CAGR of 3.84 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The...

2014-01-22 12:23:39

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Pharmerging Markets 2012-2016TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the...

2011-05-09 07:30:00

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011. "Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering...

2011-03-11 07:30:00

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and announced fourth quarter and full-year 2010 financial results. "With approximately $160 million in cash as of the end of February, we are in an excellent financial position," commented Barry D. Quart, PharmD, Ardea's president and chief executive...

2011-01-10 07:00:00

SAN DIEGO, Jan. 10, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has earned a $15 million milestone payment from Bayer HealthCare AG (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea's mitogen-activated ERK kinase (MEK) inhibitor compounds for cancer and other indications. This milestone was triggered by the initiation of a Phase 2 clinical study evaluating BAY 86-9766 in combination with...

2010-11-11 07:30:00

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that data from preclinical and clinical trials of BAY 86-9766 (formerly known as RDEA119) will be presented at the 22nd European Organisation for Research and Treatment of Cancer (EORTC) - National Cancer Institute (NCI) - American Association for Cancer Research (AACR) symposium on "Molecular Targets and Cancer Therapeutics" in Berlin, Germany. BAY 86-9766 is a mitogen-activated ERK kinase...

2010-08-06 07:30:00

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the second quarter and six months ended June 30, 2010. "Since our last quarterly update, we have presented additional clinical results further supporting RDEA594's efficacy and favorable tolerability when administered as a...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related